Evidence map›Paper›PMID 26375588›Full record

ArticlePloS one2015

Disruption of Type I Interferon Induction by HIV Infection of T Cells.

David Jesse Sanchez, Daniel Miranda, Matthew D Marsden, Thomas Michael A Dizon, Johnny R Bontemps, Sergio J Davila, Lara E Del Mundo, Thai Ha, Ashkon Senaati, Jerome A Zack and 1 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

David Jesse SanchezPharmaceutical Sciences Department, College of Pharmacy, Western University of Health Sciences, Pomona, California, United States of America.
Daniel MirandaDepartment of Microbiology, Immunology and Molecular Genetics, University of California Los Angeles, Los Angeles, California, United States of America; UCLA AIDS Institute, David Geffen School of Medicine at UCLA, Los Angeles, California, United States of America.
Matthew D MarsdenUCLA AIDS Institute, David Geffen School of Medicine at UCLA, Los Angeles, California, United States of America; Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine at UCLA, Los Angeles, California, United States of America.
Thomas Michael A DizonPharmaceutical Sciences Department, College of Pharmacy, Western University of Health Sciences, Pomona, California, United States of America.
Johnny R BontempsDepartment of Microbiology, Immunology and Molecular Genetics, University of California Los Angeles, Los Angeles, California, United States of America.
Sergio J DavilaDepartment of Microbiology, Immunology and Molecular Genetics, University of California Los Angeles, Los Angeles, California, United States of America.
Lara E Del MundoPharmaceutical Sciences Department, College of Pharmacy, Western University of Health Sciences, Pomona, California, United States of America.
Thai HaDepartment of Microbiology, Immunology and Molecular Genetics, University of California Los Angeles, Los Angeles, California, United States of America.
Ashkon SenaatiDepartment of Microbiology, Immunology and Molecular Genetics, University of California Los Angeles, Los Angeles, California, United States of America.
Jerome A ZackDepartment of Microbiology, Immunology and Molecular Genetics, University of California Los Angeles, Los Angeles, California, United States of America; UCLA AIDS Institute, David Geffen School of Medicine at UCLA, Los Angeles, California, United States of America; Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine at UCLA, Los Angeles, California, United States of America.
Genhong ChengDepartment of Microbiology, Immunology and Molecular Genetics, University of California Los Angeles, Los Angeles, California, United States of America.
University of California, Los Angeles · USWestern University of Health Sciences · USBlack AIDS Institute · US

Funding

Virology CoreP30AI028697 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ANTON, PETER A · 1991 to 2018
$39.9M
TUMOR CELL SURFACES AND CHROMOSOMEST32CA009056 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Gay M Crooks, David A. Nathanson · 1985 to 2026
$10.5M
MARC U*STAR Program at the University of California, Los AngelesT34GM008563 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MCEVOY, MEGAN M, POE, GINA R · 1996 to 2023
$9.7M
UCLA MSD ProgramR25GM055052 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI BARBER, PAUL HENRY, HASSON, TAMA W. · 1996 to 2021
$9.2M
Viral Mediated Type I Interferon InductionR01AI069120 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHENG, GENHONG · 2006 to 2021
$6.0M
Targeting HIV Reservoirs in vitro and in vivoR01AI070010 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ZACK, JEROME A. · 2006 to 2014
$3.7M
Interdisciplinary Training in Virology and Gene TherapyT32AI060567 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WU, TING-TING · 2004 to 2018
$3.4M
CLINICAL AND FUNDAMENTAL IMMUNOLOGYT32AI007126 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SAXON, ANDREW · 1985 to 2006
$1.5M
NCI NIH HHS 5T32CA009056-29NCI NIH HHS T32 CA009056NIAID NIH HHS 5T32AI007126-30NIAID NIH HHS 5T32AI060567-05NIAID NIH HHS AI028697NIAID NIH HHS AI069120-03NIAID NIH HHS AI70010NIAID NIH HHS N01 AI070010NIAID NIH HHS P30 AI028697NIAID NIH HHS R01 AI069120NIAID NIH HHS T32 AI007126NIAID NIH HHS T32 AI060567NIGMS NIH HHS 5R25GM055052-10NIGMS NIH HHS 5T34GM008563-13NIGMS NIH HHS R25 GM055052NIGMS NIH HHS T34 GM008563
6 · The paper itself

Abstract

Our main objective of this study was to determine how Human Immunodeficiency Virus (HIV) avoids induction of the antiviral Type I Interferon (IFN) system. To limit viral infection, the innate immune system produces important antiviral cytokines such as the IFN. IFN set up a critical roadblock to virus infection by limiting further replication of a virus. Usually, IFN production is induced by the recognition of viral nucleic acids by innate immune receptors and subsequent downstream signaling. However, the importance of IFN in the defense against viruses has lead most pathogenic viruses to evolve strategies to inhibit host IFN induction or responses allowing for increased pathogenicity and persistence of the virus. While the adaptive immune responses to HIV infection have been extensively studied, less is known about the balance between induction and inhibition of innate immune defenses, including the antiviral IFN response, by HIV infection. Here we show that HIV infection of T cells does not induce significant IFN production even IFN I Interferon production. To explain this paradox, we screened HIV proteins and found that two HIV encoded proteins, Vpu and Nef, strongly antagonize IFN induction, with expression of these proteins leading to loss of expression of the innate immune viral RNA sensing adaptor protein, IPS-1 (IFN-β promoter stimulator-1). We hypothesize that with lower levels of IPS-1 present, infected cells are defective in mounting antiviral responses allowing HIV to replicate without the normal antiviral actions of the host IFN response. Using cell lines as well as primary human derived cells, we show that HIV targeting of IPS-1 is key to limiting IFN induction. These findings describe how HIV infection modulates IFN induction providing insight into the mechanisms by which HIV establishes infection and persistence in a host.

Indexed as

CD4-Positive T-LymphocytesCells, CulturedCytokinesHIV-1HIV InfectionsHost-Pathogen InteractionsHuman Immunodeficiency Virus ProteinsHumansImmunity, InnateInterferon Type ISignal TransductionVirus ReplicationCytokinesHuman Immunodeficiency Virus ProteinsInterferon Type I

Identifiers

PMID26375588
PMCPMC4574156
OpenAlexW2178976198

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.